

# Adenosine Receptor A3 (ADORA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/ACF9611C8BEEEN.html>

Date: July 2022

Pages: 63

Price: US\$ 3,500.00 (Single User License)

ID: ACF9611C8BEEEN

## Abstracts

Adenosine Receptor A3 (ADORA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 - Drugs In Development, 2022, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Male Health, Oncology, Central Nervous System, Musculoskeletal Disorders, Ophthalmology and Women's Health which include indications Non-Alcoholic Steatohepatitis (NASH), Hepatocellular Carcinoma, Inflammation, Kidney Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Psoriasis, Rheumatoid Arthritis, Arthritis, Autoimmune Disorders, Chronic Kidney Disease (Chronic Renal Failure), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Female Sexual Dysfunction, Glaucoma, Male Sexual Dysfunction, Melanoma, Ocular Hypertension, Osteoarthritis Pain, Plaque Psoriasis (Psoriasis Vulgaris), Post-Operative Pain, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Prostate Cancer and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)

The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects

The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and @Scope

## Contents

Introduction

Global Markets Direct Report Coverage

Adenosine Receptor A3 (ADORA3) - Overview

Adenosine Receptor A3 (ADORA3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development

Can-Fite BioPharma Ltd

Future Medicine Co Ltd

Neumentum Inc

Palo BioFarma SL

Protheragen Inc

Adenosine Receptor A3 (ADORA3) - Drug Profiles

Cannabinoids - Drug Profile

Product Description

Mechanism Of Action

History of Events

CF-602 - Drug Profile

Product Description

Mechanism Of Action

History of Events

DPP-017 - Drug Profile

Product Description

Mechanism Of Action

FM-1203 - Drug Profile

Product Description

Mechanism Of Action

LJ-1888 - Drug Profile

Product Description

Mechanism Of Action

LJ-2698 - Drug Profile

Product Description

Mechanism Of Action

History of Events

namodenoson - Drug Profile

Product Description

Mechanism Of Action

History of Events

NTM-006 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PBF-1650 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PBF-677 - Drug Profile

Product Description

Mechanism Of Action

History of Events

piclidenoson - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile

Product Description

Mechanism Of Action

Adenosine Receptor A3 (ADORA3) - Dormant Products

Adenosine Receptor A3 (ADORA3) - Discontinued Products

Adenosine Receptor A3 (ADORA3) - Product Development Milestones

Featured News & Press Releases

Jul 11, 2022: Can-Fite to submit FDA & EMA registration plans for piclidenoson in the oral treatment of moderate to severe psoriasis

Jun 29, 2022: Can-Fite announces positive top-line results from piclidenoson phase III COMFORT study in moderate to severe psoriasis

Jun 24, 2022: Can-Fite's CF602 reverses erectile dysfunction in diabetic pre-clinical model: study published in peer-reviewed Journal Andrologia

Jun 09, 2022: Can-Fite announces publication of clinical study data for piclidenoson and namodenoson in scientific journal

May 16, 2022: Can-Fite granted key NASH Patent in Israel

May 02, 2022: Can-Fite's CEO to present Namodenoson's efficacy in liver cancer as expert speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit

Apr 05, 2022: Can-Fite is developing a topical Piclidenoson psoriasis treatment that shows efficacy in a preclinical model: potential complementary product to its phase III oral psoriasis drug

Mar 28, 2022: Can-Fite to present at Dermatology Drug Development Summit Europe on April 6, 2022

Mar 14, 2022: Can-Fite: Namodenoson's treatment of liver fibrosis receives Notice of Allowance from U.S. Patent Office

Mar 08, 2022: Can-Fite's phase III psoriasis study data expected Q2 2022

Feb 01, 2022: Can-Fite enrolls first subject in Phase IIb NASH trial

Jan 13, 2022: Prior to phase III psoriasis data release Can Fite reports that piclidenoson destroys pathological skin cells in vitro

Jan 10, 2022: Can-Fite to conduct investor meetings during the J.P. Morgan Healthcare Conference

Dec 29, 2021: Following complete clearance of cancer lesions in advanced liver cancer patient, Can-Fite is filing patent applications for the treatment of various advanced solid tumors

Dec 20, 2021: Liver cancer patient treated with Can-Fite's namodenoson clears all cancer lesions under open label extension of phase II Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022  
Number of Products under Development by Therapy Areas, 2022  
Number of Products under Development by Indications, 2022  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Number of Products under Investigation by Universities/Institutes, 2022  
Products under Investigation by Universities/Institutes, 2022  
Number of Products by Stage and Mechanism of Actions, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Pipeline by Can-Fite BioPharma Ltd, 2022  
Pipeline by Future Medicine Co Ltd, 2022  
Pipeline by Neumentum Inc, 2022  
Pipeline by Palo BioFarma SL, 2022  
Pipeline by Protheragen Inc, 2022  
Dormant Products, 2022  
Dormant Products, 2022 (Contd..1)  
Dormant Products, 2022 (Contd..2)  
Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

## I would like to order

Product name: Adenosine Receptor A3 (ADORA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/ACF9611C8BEEEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ACF9611C8BEEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

